Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells
about
Clusterin: a key player in cancer chemoresistance and its inhibitionClusterin: Review of research progress and looking ahead to direction in hepatocellular carcinomaNon-secreted clusterin isoforms are translated in rare amounts from distinct human mRNA variants and do not affect Bax-mediated apoptosis or the NF-κB signaling pathwayClusterin facilitates stress-induced lipidation of LC3 and autophagosome biogenesis to enhance cancer cell survivalNovel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients.Clusterin protects hepatocellular carcinoma cells from endoplasmic reticulum stress induced apoptosis through GRP78.Clusterin (apolipoprotein J), a molecular chaperone that facilitates degradation of the copper-ATPases ATP7A and ATP7B.Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer.Potential predictive plasma biomarkers for cervical cancer by 2D-DIGE proteomics and Ingenuity Pathway Analysis.Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma.Clusterin transcript variants expression in thyroid tumor: a potential marker of malignancy?Clusterin and COMMD1 independently regulate degradation of the mammalian copper ATPases ATP7A and ATP7BCanine models of copper toxicosis for understanding mammalian copper metabolism.The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate CancerClusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.Prognostic Role of Secretory Clusterin in Multiple Human Malignant Neoplasms: A Meta-Analysis of 26 Immunohistochemistry StudiesRelationship of clusterin with renal inflammation and fibrosis after the recovery phase of ischemia-reperfusion injuryKnockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.Downregulation of COMMD1 by miR-205 promotes a positive feedback loop for amplifying inflammatory- and stemness-associated properties of cancer cells.Potential use of custirsen to treat prostate cancer.Clusterin is a gene-specific target of microRNA-21 in head and neck squamous cell carcinoma.Novel targeted agents on the horizon for castration-resistant prostate cancer.Future directions in castrate-resistant prostate cancer therapy.Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).Functional understanding of the versatile protein copper metabolism MURR1 domain 1 (COMMD1) in copper homeostasis.FMNL2 destabilises COMMD10 to activate NF-κB pathway in invasion and metastasis of colorectal cancer.Heat shock proteins in hepatocellular carcinoma: Molecular mechanism and therapeutic potential.COMMD7 as a novel NEMO interacting protein involved in the termination of NF-κB signaling.Calcium oxalate calculi-induced clusterin expression in kidney.Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models.Clusterin as a therapeutic target.Exosomes as biomarker enriched microvesicles: characterization of exosomal proteins derived from a panel of prostate cell lines with distinct AR phenotypes.GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer.Cotargeting stress-activated Hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer.From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.The Antitumor Peptide CIGB-552 Increases COMMD1 and Inhibits Growth of Human Lung Cancer Cells.Transcriptome-Based Analysis of Molecular Pathways for Clusterin Functions in Kidney Cells.Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen.COMMD1: A Multifunctional Regulatory Protein.
P2860
Q24567925-ED3D5C94-F609-4CE7-A9F3-ABCCECF7ABB4Q26799048-80F2377B-59CD-4C49-A926-5DF1FEB57EDAQ27305342-ABEA7478-5E5A-4797-A54D-BA883BB05965Q30611108-486D75EC-B76B-4C88-A674-7DF8AB366A38Q33887173-35BE2DFD-A80C-4EB4-9D94-41C96EBD5154Q34606433-80AD4270-75DB-44BF-9436-A7FBAC233071Q34695507-3C8CB7ED-B537-4374-8DC1-3892E55F012CQ35058278-6DB63018-F8E0-4F80-943D-D033538C1BA8Q35452689-C1DB4BFC-692D-4FF7-B85C-ECAFDA44CA7AQ35550129-353B786A-5EFB-4BA1-8138-79E1F54E4176Q35576778-4F18A6FF-FB75-4EFC-B05A-FD68A081A054Q35709894-BA4CC054-44D7-4CCB-99C7-6B401541EACDQ35745611-2AA3B55F-16CF-409F-B330-391348CBD239Q35882782-7B9536C2-1D1C-438F-B553-1151670EDFB9Q36072803-1454F8C7-A454-4921-9E48-A82128478E4CQ36105571-7E3F820E-09DC-4E89-9615-9279C47EAF3FQ36138680-283D69AC-399F-42D3-B754-BA8C40262C7FQ36579884-DA395B34-C999-465D-9715-6858E370C561Q36799298-3F263608-C740-4FD9-B776-C6F0B3AFD858Q36975969-9628F3F5-3B43-4E44-BE29-ECEF9C6FE2E2Q37673301-63BB8060-ECBB-457D-A75A-A5A0D00DE26DQ37818294-817E157B-C861-403C-BD1D-16193C86FD47Q37826274-B002AFD3-300A-4945-A75E-891F019DFDFCQ37950459-11ADE179-4809-400F-A99C-47070B8F4F94Q38201800-70FCF073-CF28-4406-8D53-2BD346795185Q38619750-B2E27C92-E66D-4E2E-924C-55675E78C78EQ38725577-3515418F-0474-48F2-A252-D9D69C6EF5D2Q38865492-F6B08724-4319-427D-9010-7BD41F4A1A45Q38872845-12E1B8CC-A333-493A-B106-E9915048F535Q38973458-EDDCBAA8-D969-4291-89F7-DE31D084823FQ39039324-D337067F-7AD7-4922-84E7-C99E9BB78121Q39326999-E8064D84-8CC4-473F-8F6B-76BC71EC8BA6Q39332931-B7DE22DF-A567-4F75-991D-97FA05F128C0Q39335548-C000A90B-E16B-4A38-BD20-59EE18AA11D0Q39354603-AD317375-CE08-4282-A7E2-F4D141883AD8Q39468730-5EFC3E83-50B8-4FEF-BDE2-11F480B6120EQ39786753-AF595AE4-CEDF-4F12-A2A0-26819A9F6891Q41887988-86FF9D79-CD9E-459F-892A-028913CEF184Q42685237-C50C3150-6ECF-42CA-8E7A-F8BBF328A4BAQ46360947-AAD44B74-1812-4CE0-B1BB-D5D0A10871C0
P2860
Clusterin facilitates COMMD1 and I-kappaB degradation to enhance NF-kappaB activity in prostate cancer cells
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clusterin facilitates COMMD1 a ...... ivity in prostate cancer cells
@ast
Clusterin facilitates COMMD1 a ...... ivity in prostate cancer cells
@en
Clusterin facilitates COMMD1 a ...... ivity in prostate cancer cells
@en-gb
Clusterin facilitates COMMD1 a ...... ivity in prostate cancer cells
@nl
type
label
Clusterin facilitates COMMD1 a ...... ivity in prostate cancer cells
@ast
Clusterin facilitates COMMD1 a ...... ivity in prostate cancer cells
@en
Clusterin facilitates COMMD1 a ...... ivity in prostate cancer cells
@en-gb
Clusterin facilitates COMMD1 a ...... ivity in prostate cancer cells
@nl
prefLabel
Clusterin facilitates COMMD1 a ...... ivity in prostate cancer cells
@ast
Clusterin facilitates COMMD1 a ...... ivity in prostate cancer cells
@en
Clusterin facilitates COMMD1 a ...... ivity in prostate cancer cells
@en-gb
Clusterin facilitates COMMD1 a ...... ivity in prostate cancer cells
@nl
P2093
P2860
P3181
P1476
Clusterin facilitates COMMD1 a ...... ivity in prostate cancer cells
@en
P2093
Amina Zoubeidi
Anousheh Zardan
Colleen C Nelson
Eliana Beraldi
Leo W J Klomp
Martin E Gleave
Paul S Rennie
Susan Ettinger
P2860
P304
P3181
P356
10.1158/1541-7786.MCR-09-0277
P407
P577
2010-01-01T00:00:00Z